Sangamo Therapeutics Announces First Quarter 2026 Earnings Call
Click here to view
Careers
Core Values
Open Positions
Employee Benefits
Clinical Trials
Contact
Science
Technology Platforms
Zinc Finger Platform
Delivery Platform
Modular Integrase (MINT) Platform
Therapeutic Applications
Neurology
Oncology
Presentations
Publications
Programs
Pipeline
Clinical Programs
Small Fiber Neuropathy (SFN)
Fabry Disease
Hemophilia A
Clinical Trials
Collaborations & Partners
Patients
Our Commitment
Expanded Access Policy
Bioethics
Patient Stories
Bryan – Fabry Disease
Lori – Fabry Disease
Matt – Fabry Disease
Elizabeth – Fabry Disease
Israel – Hemophilia A
Miles – Hemophilia A
Trevor – Prion Disease
Sharron – Renal Transplant
Patient Focus
Resources
Education
Organizations
Investors & Media
Overview
News Releases
Events
Presentations
ESG
About
Overview
Mission & Vision
Executive Leadership
Board of Directors
Latest News
News Releases
Events
Presentations
Contact
Science
Technology Platforms
Zinc Finger Platform
Delivery Platform
Modular Integrase (MINT) Platform
Therapeutic Applications
Neurology
Oncology
Presentations
Publications
Programs
Pipeline
Clinical Programs
Small Fiber Neuropathy (SFN)
Fabry Disease
Hemophilia A
Clinical Trials
Collaborations & Partners
Patients
Our Commitment
Expanded Access Policy
Bioethics
Patient Stories
Bryan – Fabry Disease
Lori – Fabry Disease
Matt – Fabry Disease
Elizabeth – Fabry Disease
Israel – Hemophilia A
Miles – Hemophilia A
Trevor – Prion Disease
Sharron – Renal Transplant
Patient Focus
Resources
Education
Organizations
Investors & Media
Overview
News Releases
Events
Presentations
ESG
About
Overview
Mission & Vision
Executive Leadership
Board of Directors
Latest News
News Releases
Events
Presentations
Contact
LinkedIn
Twitter
Scientific & Medical Presentations
Neurology Conference Presentations Hub
ASGCT 2026
Poster: ST-503 nonclinical safety studies evaluating zinc finger repressors regulating expression of the Nav1.7 gene for treatment of small fiber neuropathy
ASGCT 2026
Poster: Single-cell characterization of ST-506, a BBB-penetrant epigenetic repressor of prion protein expression, in the nonhuman primate brain
ASGCT 2026
Presentation: Zinc finger fusions and synthetic DNA donor engineering improve the performance of reprogrammed modular integrases at the TRAC locus
WORLDSymposium 2026
Presentation: Isaralgagene civaparvovec (ST-920) shows positive mean annualized eGFR slope in adults with Fabry disease: Topline results from the registrational Phase 1/2 STAAR gene therapy study and long-term follow-up study
WORLDSymposium 2026
Presentation: Isaralgagene civaparvovec (ST-920) shows stable cardiac function over one year in patients with Fabry disease: Results from the registrational Phase 1/2 STAAR gene therapy study
WORLDSymposium 2026
Presentation: Isaralgagene civaparvovec (ST-920) gene therapy for adults with Fabry disease: Pharmacology and immunogenicity outcomes from the Phase 1/2 STAAR study and ongoing long-term follow-up
WORLDSymposium 2026
Presentation: A combined fertility, embryofetal development, AAV integration and germline transmission risk study in mice with ST-920 (isaralgagene civaparvovec) for Fabry disease
Prion 2025
Poster: ST-506 mediates brainwide lowering of prion protein in nonhuman primates via a conserved blood-brain-barrier crossing mechanism, as a potential one-time treatment for prion disease
9th International Congress on Neuropathic Pain
Poster: Preclinical Development of ST-503: an Investigational Adeno-associated Viral Vector Delivered Zinc Finger Repressor Novel Epigenetic Therapy for Idiopathic Small Fiber Neuropathy
ICIEM
Poster: Isaralgagene Civaparvovec (ST-920) Shows Positive Mean Annualized eGFR Slope in Adults with Fabry Disease: Updated Results from the Registrational Phase 1/2 STAAR Gene Therapy Study
WORLDSymposium 2025
Presentation: Isaralgagene Civaparvovec (ST-920) Gene Therapy in Adults with Fabry Disease: Updated Results from an Ongoing Phase 1/2 Study (STAAR)
WORLDSymposium 2025
Poster: Isaralgagene Civaparvovec (ST-920) Gene Therapy in Adults with Fabry Disease: Updated Results from an Ongoing Phase 1/2 Study (STAAR)
ASH 2024
Efficacy and Safety of Giroctocogene Fitelparvovec in Adults With Moderately Severe to Severe Hemophilia A: Primary Analysis Results From the Phase 3 AFFINE Gene Therapy Trial
Prion 2024
Presentation: Single Intravenous Treatment with Zinc Finger Repressor Leads to Brainwide Reduction of Prion in Nonhuman Primates and Significantly Prolongs Survival in the RML Mouse Model
ASGCT 2024
Presentation: A Highly Potent Engineered AAV Capsid, STAC-150, Enables High-Throughput AAV Production and Arrayed Epigenetic Regulator Screening Directly in Cultured Neurons
ASGCT 2024
Presentation: Directed Evolution of Bxb1 for the Development of Modular Integrases (MINTS)
ASGCT 2024
Presentation: Identification and Characterization of STAC-BBB, an Engineered AAV Capsid That Exhibits Widespread Transduction of the Central Nervous System in Cynomolgus Macaques
ASGCT 2024
Poster: Site-directed integration of large DNA sequences into endogenous sites in the human genome using engineered Modular Integrases (MINTS)
ASGCT 2024
Poster: Highly Specific Zinc Finger Proteins with Synthetic Target Sites Enable Self-Regulated Expression of Dosage-Sensitive Transgenes
ASGCT 2024
Poster: Zinc Finger Mediated Repression and Replacement of MFN2 Leads to the Rescue of Cellular Disease Phenotype in CMT2A Patient-Derived Cells
ASGCT 2024
Poster: Process and Formulation Development for a Novel Blood-Brain Barrier Penetrant AAV Capsid
ASGCT 2024
Poster: Unraveling Impact of Manufacturing Process-Related Stresses on AAV Stability, Aggregation, and DNA Release
ASGCT 2024
Poster: Development of Blood-Brain Barrier Penetrant AAVs through Receptor-Targeted Capsid Engineering
ASGCT 2024
Poster: Optimal Drug Product Presentation and Container Closure Selection for AAV-Based Genomic Medicines
ASGCT 2024
Poster: Epigenetic Regulation of Human Prion Expression as a Potential One-Time Treatment for Prion Disease
ASGCT 2024
Poster: Development of a Robust Zinc Finger Activation Platform for Treatment of Neurological Disorders
ASGCT 2024
Poster: Shank3 Gene Activation Mediated by Zinc Finger Transcriptional Activators (ZFA) as a Therapeutic Approach for Phelan-McDermid Syndrome
ASGCT 2024
Poster: PMP22 Gene Repression Mediated by Zinc Finger Repressors (ZFRs) as a Therapeutic Approach for CMT1A
ASGCT 2024
Poster: SOD1 Gene Repression Mediated by Zinc Finger Repressors (ZFRs) as a Therapeutic Approach for SOD1-Mediated ALS
ASGCT 2024
Poster: Widespread CNS Tau Knockdown for the Potential Treatment of Alzheimer’s Disease and other Tauopathies
ASGCT 2024
Poster: UBE3A Gene Activation Mediated by Zinc Finger Activators (ZFAs) as a Therapeutic Approach for Angelman Syndrome
ASGCT 2024
Poster: SNCA Gene Repression Mediated by Zinc Finger Repressors (ZFRs) as a Therapeutic Approach for Parkinson’s Disease
ASGCT 2024
Poster: A Zinc Finger Activator Platform to Restore Normal Gene & Protein Expression in Cellular Models of Dravet Syndrome
ASGCT 2024
Poster: Restoration of Normal Gene and Protein Expression in Mouse and Human Disease Models of SCN2A Haploinsufficiency Using Zinc Finger Activators
WORLDSymposium 2024
Presentation: Isaralgagene civaparvovec (ST-920) gene therapy in adults with Fabry disease: Updated results from an ongoing phase 1/2 study (STAAR)
WORLDSymposium 2024
Poster: Isaralgagene civaparvovec (ST-920) gene therapy in adults with Fabry disease: Updated results from an ongoing phase 1/2 study (STAAR)
WORLDSymposium 2024
Presentation: A 3-month gene therapy single-dose IV administration pharmacology and safety study with ST-920 (isaralgagene civaparvovec) for Fabry disease in mice
WORLDSymposium 2024
Poster: A 3-month gene therapy single-dose IV administration pharmacology and safety study with ST-920 (isaralgagene civaparvovec) for Fabry disease in mice
WORLDSymposium 2024
Poster: Anti-AAV6 antibody assay for patient enrollment supporting ST-920 phase 1/2 study for Fabry disease
ASH 2023
Four-Year Follow-up of the Alta Study, a Phase 1/2 Study of Giroctocogene Fitelparvovec (PF-07055480/SB-525) Gene Therapy in Adults With Severe Hemophilia A
CRL Biotechnology Symposium 2023
Preclinical Development of a Zinc Finger Transcriptional Repressor Targeting the SCN9A Gene as a Novel Therapy for Peripheral Neuropathic Pain
American College of Toxicology 2023
Preclinical Development of a Novel Gene Therapy for the Treatment of Peripheral Neuropathic Pain Through Zinc Finger Repressor- Mediated Repression of the SCN9A Gene
Annual Pain Therapeutics Summit 2023
Zinc finger mediated epigenetic repression of SCN9A gene as a therapeutic approach for painful peripheral neuropathies
ESGCT 2023
Multiplex targeting of immune checkpoints with compact zinc finger repressors to improve anti-tumor activity of T cells
ESGCT 2023
Zinc Finger Activators restore normal gene and protein expression in a mouse model of SCN2A haploinsufficiency
ESGCT 2023
Shank3 Gene Activation Mediated by Zinc Finger Activators (ZF-As) as a Therapeutic Approach for Phelan-McDermid Syndrome
ESGCT 2023
Multimerization of Chimeric Antigen Receptor (CAR) binding domains: A solution to assess tissue specificity of low to medium affinity scFv
Prion 2023
Neuron-Specific Expression of Zinc-Finger Repressors Mediate Widespread Prion Reduction in the Brain for the Potential Treatment of Prion Disease
ASGCT 2023
Zinc Finger Transcriptional Regulator Mediated Repression of SCN9A Gene as a Therapeutic Approach for Painful Peripheral Neuropathies
ASGCT 2023
Engineered Zinc Finger Transcriptional Regulators Specifically Reduce Prion Expression and Extend Survival in an Aggressive Prion Disease Model